MARKET

TRDA

TRDA

Entrada Therapeutics, Inc.
NASDAQ
7.03
+0.16
+2.33%
Opening 10:26 08/10 EDT
OPEN
6.87
PREV CLOSE
6.87
HIGH
7.08
LOW
6.87
VOLUME
65.79K
TURNOVER
--
52 WEEK HIGH
16.45
52 WEEK LOW
4.930
MARKET CAP
273.72M
P/E (TTM)
-1.7718
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Janux Therapeutics Inc (JANX) and Entrada Therapeutics Inc (TRDA)
TipRanks · 3h ago
Weekly Report: what happened at TRDA last week (0803-0807)?
Weekly Report · 5h ago
Entrada Q2 Loss Shrinks; Data From Phase 1/2 Trials In DMD And DM1 Expected In '27
NASDAQ · 3d ago
Analysts’ Top Healthcare Picks: Insulet (PODD), Entrada Therapeutics Inc (TRDA)
TipRanks · 4d ago
Entrada Therapeutics reports Q2 results
Seeking Alpha · 4d ago
Press Release: Entrada Therapeutics Reports -2-
Dow Jones · 5d ago
Big Insider Moves Rock Entrada Therapeutics as Key Players Cut Their Stakes
TipRanks · 6d ago
Compugen (CGEN) Reports Q2 Loss, Misses Revenue Estimates
NASDAQ · 08/03 12:05
More
About TRDA
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.

Webull offers Entrada Therapeutics Inc stock information, including NASDAQ: TRDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRDA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRDA stock methods without spending real money on the virtual paper trading platform.